Top

Published in:

01-03-2013 | Brief Communication

Locally Ablative Non-surgical Management of Colo-rectal Liver Metastasis

Authors: Amit Bahl, Rakesh Kapoor, Pramod Kumar Singh, Tapesh Bhattacharya, Oinam S. Arun, Tomar Parsee, Suresh C. Sharma

Published in: Journal of Gastrointestinal Cancer | Issue 1/2013

Abstract

Background

Liver is one of the commonest sites of metastasis in colorectal cancer patients. Solitary liver metastasis or oligometastasis are traditionally treated by surgical resection or chemotherapy.

Discussion

There may be a subgroup of these patients who are not suitable for surgery or chemotherapy due to various co-morbid factors. These patients can be treated by novel minimally invasive or noninvasive ablative techniques like interstitial brachytherapy, extracranial stereotactic radiotherapy, and radiofrequency ablation.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRef

Steele G, Ravikumar TS. Resection of hepatic metastases from colorectal cancer: biologic perspective. Ann Surg. 1989;210:127–38.PubMedCrossRef

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in ironotecan refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–45.PubMedCrossRef

Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaloplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.PubMedCrossRef

Van Custem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy refractory metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–34.CrossRef

Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawerence TS, Ten Haken RK, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–21.PubMedCrossRef

Ruhl R, Ludemann L, Czarnecka A, Streitparth F, Seidensticker M, Mohnike K, et al. Radiobiological restrictions and tolerance doses of repeated single-fraction HDR-irradiation of intersecting small liver volumes for recurrent hepatic metastases. Radiat Oncol. 2010;5:44.PubMedCrossRef

Llovet JM, Sala M, Bruix J. Nonsurgical treatment of hepatocellular carcinoma. Liver Transpl. 2000;6:S11–5.PubMedCrossRef

Ricke J, Mohnike K, Pech M, Seidensticker M, Ruhl R, Weiners G, et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2010;78:479–85.PubMedCrossRef

10.

Bahl A, Sharma DN, Basu J, Rath GK, Julka PK. Interstitial brachytherapy in liver metastasis. Ann Oncol. 2009;20:V18.CrossRef

11.

Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiotherapy of extracranial tumors using an accelerator. Clinical experience of first thirty one patients. Acta Oncol. 1995;34:861–70.PubMedCrossRef

12.

Goodman KA, Weigner EA, Maturen KE, Zhang Z, Mo Q, Yang G, et al. Dose-escalation study of single fraction stereotactic radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78:486–93.PubMedCrossRef

13.

Case RB, Moseley DJ, Sonke JJ, Eccles CL, Dinniwell RE, Kim J, et al. Interfraction and intrafraction changes in amplitude of breathing motion in stereotactic liver radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77:918–25.PubMedCrossRef

14.

Son SH, Choi BO, Ryu MR, Kang YN, Jang JS, Bae SH, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose volumetric parameters predicting the hepatic complications. Int J Radiat Oncol Biol Phys. 2010;78:1073–80.PubMedCrossRef

15.

Murphy JD, Skieller CC, Kim J, Dietreich S, Chang DT, Koong AC. A dosimetric model for duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010;78:1420–6.PubMedCrossRef

16.

Rosenthal DI, Hornicek FJ, Wolfe MW, Jennings LC, Gebhardt MC, Mankin HJ. Percutaneous radiofrequency coagulation of osteoid osteomas compared with operative treatment. J Bone Joint Surg Am. 1998;80:815–21.PubMed

17.

Wood BJ, Ramkaransingh JR, Fojo T, Walther MM, Libutti SK. Percutaneous tumor ablation with radiotherapy. Cancer. 2002;94:443–51.PubMedCrossRef

18.

Noguchi M. Minimally invasive surgery for small breast cancer. J Surg Oncol. 2003;84:94–101.PubMedCrossRef

19.

Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, et al. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg. 2006;141:181–90.PubMedCrossRef

20.

Larson TR, Bostwick DG, Corica A. A temperature correlated histopathological change following microwave thermoablation of obstructive tissues in patients with benign prostate hyperplasia. Urology. 1996;47:463–9.PubMedCrossRef

21.

Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28:493–508.PubMedCrossRef

22.

Rath GK, Julka PK, Thulkar S, Sharma DN, Bahl A, Bhatnagar S. Radiofrequency ablation of hepatic metastasis. Results of treatment in forty patients. J Cancer Res Ther. 2008;4:14–7.PubMedCrossRef

Title: Locally Ablative Non-surgical Management of Colo-rectal Liver Metastasis
Authors: Amit Bahl
Rakesh Kapoor
Pramod Kumar Singh
Tapesh Bhattacharya
Oinam S. Arun
Tomar Parsee
Suresh C. Sharma
Publication date: 01-03-2013
Publisher: Springer US
Published in: Journal of Gastrointestinal Cancer / Issue 1/2013
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-012-9427-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Locally Ablative Non-surgical Management of Colo-rectal Liver Metastasis

Abstract

Background

Discussion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Discussion

Please log in to get access to this content

Other articles of this Issue 1/2013

Understanding the Symptom Experience of Patients with Gastrointestinal Cancers in the First Year Following Diagnosis: Findings from a Qualitative Longitudinal Study

Burden of Emergency and Non-emergency Colorectal Cancer Surgeries in West Virginia and the USA

Evaluation of a Prospective Surgical Strategy of Extended Resection to Achieve R0 Status in Gall Bladder Cancer

Characteristics of Colorectal Cancer Survival in an Urban County Hospital

Comparative Effectiveness of Chemotherapy in Elderly Patients with Metastatic Colorectal Cancer

Anorectal Metastasis from Breast Carcinoma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page